NEW YORK, July 9, 2020 /PRNewswire/ --
Global Gene Therapy Market to Reach US$4.2 Billion by the Year 2027 Amid the COVID-19 crisis, the global market for Gene Therapy estimated at US$701.2 Million in the year 2020, is projected to reach a revised size of US$4.2 Billion by 2027, growing at a CAGR of 29.3% over the analysis period 2020-2027.Lentivirus, one of the segments analyzed in the report, is projected to grow at a 21.7% CAGR to reach US$130.1 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the AAV segment is readjusted to a revised 24.9% CAGR for the next 7-year period. This segment currently accounts for a 13.5% share of the global Gene Therapy market.
Read the full report: https://www.reportlinker.com/p05817594/?utm_source=PRN
The U.S. Accounts for Over 26.8% of Global Market Size in 2020, While China is Forecast to Grow at a 36.3% CAGR for the Period of 2020-2027 The Gene Therapy market in the U.S. is estimated at US$188.2 Million in the year 2020. The country currently accounts for a 26.84% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$1.1 Billion in the year 2027 trailing a CAGR of 36.3% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 23.2% and 26.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 25.1% CAGR while Rest of European market (as defined in the study) will reach US$1.1 Billion by the year 2027.
RetroVirus & Gamma RetroVirus Segment Corners a 55.5% Share in 2020 In the global RetroVirus & Gamma RetroVirus segment, USA, Canada, Japan, China and Europe will drive the 28.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$293.4 Million in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$662.2 Million by the year 2027, while Latin America will expand at a 30.1% CAGR through the analysis period. We bring years of research experience to this 16th edition of our report. The 248-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
- Competitors identified in this market include, among others,
Read the full report: https://www.reportlinker.com/p05817594/?utm_source=PRN
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW Global Competitor Market Shares Gene Therapy Competitor Market Share Scenario Worldwide (in %): 2019 & 2028 Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE Table 1: Gene Therapy Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027
Table 2: Gene Therapy Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019
Table 3: Gene Therapy Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027
Table 4: Lentivirus (Vector) World Market by Region/Country in US$ Thousand: 2020 to 2027
Table 5: Lentivirus (Vector) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019
Table 6: Lentivirus (Vector) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027
Table 7: AAV (Vector) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027
Table 8: AAV (Vector) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019
Table 9: AAV (Vector) Market Sales Breakdown by Region/Countryin Percentage: 2012 VS 2020 VS 2027
Table 10: RetroVirus & Gamma RetroVirus (Vector) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027
Table 11: RetroVirus & Gamma RetroVirus (Vector) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019
Table 12: RetroVirus & Gamma RetroVirus (Vector) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027
Table 13: Modified Herpes Simplex Virus (Vector) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2020to 2027
Table 14: Modified Herpes Simplex Virus (Vector) Market Historic Review by Region/Country in US$ Thousand: 2012 to 2019
Table 15: Modified Herpes Simplex Virus (Vector) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027
Table 16: Adenovirus (Vector) World Market by Region/Country in US$ Thousand: 2020 to 2027
Table 17: Adenovirus (Vector) Historic Market Analysis byRegion/Country in US$ Thousand: 2012 to 2019
Table 18: Adenovirus (Vector) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027
Table 19: Other Applications (Vector) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020 to 2027
Table 20: Other Applications (Vector) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2012 to 2019
Table 21: Other Applications (Vector) Market Percentage Share Distribution by Region/Country: 2012 VS 2020 VS 2027
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES Market Facts & Figures US Gene Therapy Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 22: United States Gene Therapy Market Estimates and Projections in US$ Thousand by Vector: 2020 to 2027
Table 23: Gene Therapy Market in the United States by Vector: A Historic Review in US$ Thousand for 2012-2019
Table 24: United States Gene Therapy Market Share Breakdown by Vector: 2012 VS 2020 VS 2027
CANADA Table 25: Canadian Gene Therapy Market Estimates and Forecasts in US$ Thousand by Vector: 2020 to 2027
Table 26: Canadian Gene Therapy Historic Market Review by Vector in US$ Thousand: 2012-2019
Table 27: Gene Therapy Market in Canada: Percentage Share Breakdown of Sales by Vector for 2012, 2020, and 2027
JAPAN Table 28: Japanese Market for Gene Therapy: Annual Sales Estimates and Projections in US$ Thousand by Vector for the Period 2020-2027
Table 29: Gene Therapy Market in Japan: Historic Sales Analysisin US$ Thousand by Vector for the Period 2012-2019
Table 30: Japanese Gene Therapy Market Share Analysis by Vector: 2012 VS 2020 VS 2027
CHINA Table 31: Chinese Gene Therapy Market Growth Prospects in US$Thousand by Vector for the Period 2020-2027
Table 32: Gene Therapy Historic Market Analysis in China in US$ Thousand by Vector: 2012-2019
Table 33: Chinese Gene Therapy Market by Vector: Percentage Breakdown of Sales for 2012, 2020, and 2027
EUROPE Market Facts & Figures European Gene Therapy Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Market Analytics Table 34: European Gene Therapy Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027
Table 35: Gene Therapy Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period2012-2019
Table 36: European Gene Therapy Market Share Shift by Region/Country: 2012 VS 2020 VS 2027
Table 37: European Gene Therapy Market Estimates and Forecasts in US$ Thousand by Vector: 2020-2027
Table 38: Gene Therapy Market in Europe in US$ Thousand by Vector: A Historic Review for the Period 2012-2019
Table 39: European Gene Therapy Market Share Breakdown byVector: 2012 VS 2020 VS 2027
FRANCE Table 40: Gene Therapy Market in France by Vector: Estimates and Projections in US$ Thousand for the Period 2020-2027
Table 41: French Gene Therapy Historic Market Scenario in US$ Thousand by Vector: 2012-2019
Table 42: French Gene Therapy Market Share Analysis by Vector: 2012 VS 2020 VS 2027
GERMANYTable 43: Gene Therapy Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Vector for the Period2020-2027
Table 44: German Gene Therapy Historic Market Analysis in US$ Thousand by Vector: 2012-2019
Table 45: German Gene Therapy Market Share Breakdown by Vector: 2012 VS 2020 VS 2027
ITALY Table 46: Italian Gene Therapy Market Growth Prospects in US$ Thousand by Vector for the Period 2020-2027
Table 47: Gene Therapy Historic Market Analysis in Italy in US$ Thousand by Vector: 2012-2019
Table 48: Italian Gene Therapy Market by Vector: Percentage Breakdown of Sales for 2012, 2020, and 2027
UNITED KINGDOM Table 49: United Kingdom Market for Gene Therapy: Annual Sales Estimates and Projections in US$ Thousand by Vector for thePeriod 2020-2027
Table 50: Gene Therapy Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Vector for the Period 2012-2019
Table 51: United Kingdom Gene Therapy Market Share Analysis byVector: 2012 VS 2020 VS 2027
SPAIN Table 52: Spanish Gene Therapy Market Estimates and Forecasts in US$ Thousand by Vector: 2020 to 2027
Table 53: Spanish Gene Therapy Historic Market Review by Vector in US$ Thousand: 2012-2019
Table 54: Gene Therapy Market in Spain: Percentage Share Breakdown of Sales by Vector for 2012, 2020, and 2027
RUSSIATable 55: Russian Gene Therapy Market Estimates and Projections in US$ Thousand by Vector: 2020 to 2027
Table 56: Gene Therapy Market in Russia by Vector: A Historic Review in US$ Thousand for 2012-2019
Table 57: Russian Gene Therapy Market Share Breakdown byVector: 2012 VS 2020 VS 2027
REST OF EUROPE Table 58: Rest of Europe Gene Therapy Market Estimates and Forecasts in US$ Thousand by Vector: 2020-2027
Table 59: Gene Therapy Market in Rest of Europe in US$ Thousand by Vector: A Historic Review for the Period 2012-2019
Table 60: Rest of Europe Gene Therapy Market Share Breakdown by Vector: 2012 VS 2020 VS 2027
ASIA-PACIFIC Table 61: Asia-Pacific Gene Therapy Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027
Table 62: Gene Therapy Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2012-2019
Table 63: Asia-Pacific Gene Therapy Market Share Analysis by Region/Country: 2012 VS 2020 VS 2027
Table 64: Gene Therapy Market in Asia-Pacific by Vector: Estimates and Projections in US$ Thousand for the Period 2020-2027
Table 65: Asia-Pacific Gene Therapy Historic Market Scenario in US$ Thousand by Vector: 2012-2019
Table 66: Asia-Pacific Gene Therapy Market Share Analysis by Vector: 2012 VS 2020 VS 2027
AUSTRALIA Table 67: Gene Therapy Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Vector for the Period 2020-2027
Table 68: Australian Gene Therapy Historic Market Analysis in US$ Thousand by Vector: 2012-2019
Table 69: Australian Gene Therapy Market Share Breakdown byVector: 2012 VS 2020 VS 2027
INDIA Table 70: Indian Gene Therapy Market Estimates and Forecasts in US$ Thousand by Vector: 2020 to 2027
Table 71: Indian Gene Therapy Historic Market Review by Vectorin US$ Thousand: 2012-2019
Table 72: Gene Therapy Market in India: Percentage Share Breakdown of Sales by Vector for 2012, 2020, and 2027
SOUTH KOREA Table 73: Gene Therapy Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Vector for thePeriod 2020-2027
Table 74: South Korean Gene Therapy Historic Market Analysis in US$ Thousand by Vector: 2012-2019
Table 75: Gene Therapy Market Share Distribution in South Korea by Vector: 2012 VS 2020 VS 2027
REST OF ASIA-PACIFIC Table 76: Rest of Asia-Pacific Market for Gene Therapy: Annual Sales Estimates and Projections in US$ Thousand by Vector for the Period 2020-2027
Table 77: Gene Therapy Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Vector for the Period2012-2019
Table 78: Rest of Asia-Pacific Gene Therapy Market Share Analysis by Vector: 2012 VS 2020 VS 2027
LATIN AMERICA Table 79: Latin American Gene Therapy Market Trends by Region/Country in US$ Thousand: 2020-2027
Table 80: Gene Therapy Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2012-2019
Table 81: Latin American Gene Therapy Market PercentageBreakdown of Sales by Region/Country: 2012, 2020, and 2027
Table 82: Latin American Gene Therapy Market Growth Prospects in US$ Thousand by Vector for the Period 2020-2027
Table 83: Gene Therapy Historic Market Analysis in Latin America in US$ Thousand by Vector: 2012-2019
Table 84: Latin American Gene Therapy Market by Vector: Percentage Breakdown of Sales for 2012, 2020, and 2027
ARGENTINA Table 85: Argentinean Gene Therapy Market Estimates andForecasts in US$ Thousand by Vector: 2020-2027
Table 86: Gene Therapy Market in Argentina in US$ Thousand by Vector: A Historic Review for the Period 2012-2019
Read more from the original source:
Global Gene Therapy Industry - PRNewswire
- Unraveling The Complexity Of Cell Therapy: Advancements And Challenges - Life Science Leader Magazine - November 27th, 2024
- Novartis wagers more than $1B on gene therapies for the nervous system - BioPharma Dive - November 27th, 2024
- Gene therapy for geographic atrophy in age-related macular degeneration: current insights - Nature.com - November 27th, 2024
- Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - STAT - November 27th, 2024
- At MGB's gene therapy institute, effort to win first venture capital investments continues - The Business Journals - November 27th, 2024
- Neurogene reports death of Rett patient left in critical condition by high dose of gene therapy - Fierce Biotech - November 27th, 2024
- Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy - CGTLive - November 27th, 2024
- Why This Gene-Therapy Companys Stock Is Rising 228% - Yahoo! Voices - November 27th, 2024
- How Minaris is Tackling the Scalability Challenge in Cell and Gene Therapy: A Conversation with CEO, Dr. Hiroto Bando - geneonline - November 27th, 2024
- RNA editing is the next frontier in gene therapy heres what you need to know - The Conversation - November 27th, 2024
- Assessment of gene therapy viral vectors in RPE cells - News-Medical.Net - November 27th, 2024
- Retinal organoids and RPE models for retinal gene therapy development - News-Medical.Net - November 27th, 2024
- China Vows to Bolster Gene Therapy Research in Key Biotech Hub - Bloomberg - November 27th, 2024
- Gene Therapy - Volume 31 Issue 11-12, November 2024 - Nature.com - November 27th, 2024
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - GlobeNewswire - November 27th, 2024
- Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - MedCity News - November 27th, 2024
- New CRISPR system pauses genes, rather than turning them off permanently - Livescience.com - November 27th, 2024
- Liver-targeting gene therapy lowers mice whole-body SMA symptoms - SMA News Today - November 27th, 2024
- Bright breakthroughs: Real stories of beating rare disease - Science - November 27th, 2024
- Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA... - November 27th, 2024
- A Year of DMD Gene Therapy Trial Failures - AJMC.com Managed Markets Network - November 3rd, 2024
- Hemophilia B: Gene Therapy Shows Promise - Medscape - November 3rd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 30, 2024 - CGTLive - November 3rd, 2024
- 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - PharmaVoice - November 3rd, 2024
- Cell therapy weekly: support for commercialization of complex therapies - RegMedNet - November 3rd, 2024
- Lexeo shares early data on Alzheimers gene therapy - Endpoints News - November 3rd, 2024
- Medicaid Aiming to Improve Patient Access to High-Cost Therapies - AJMC.com Managed Markets Network - November 3rd, 2024
- The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP - Neurology Live - November 3rd, 2024
- OHSU researchers identify gene that could be key to future HIV vaccine - OHSU News - November 3rd, 2024
- Purespring gene therapy reduces kidney scarring in mice and is stably expressed in pigs - Fierce Biotech - November 3rd, 2024
- Data Roundup: October 2024 Features Update for TCR-Based Autologous Cell Therapy in Melanoma, the First Clinical Demonstration of Therapeutic RNA... - November 3rd, 2024
- NewBiologix Launches Xcell to Accelerate, Optimize, and Scale Gene and Cell Therapy Production - Business Wire - November 3rd, 2024
- Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy: the 200 Best Inventions of 2024 - TIME - November 3rd, 2024
- Addressing gene and cell therapy commercialization challenges - TechTarget - November 3rd, 2024
- University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first - The Business Journals - November 3rd, 2024
- Roche will aim to tackle gene therapy challenges through Dyno deal - The Pharma Letter - November 3rd, 2024
- Behind the Breakthroughs: How to Turn $1,000,000 CAR Ts into Real Medicines - Inside Precision Medicine - November 3rd, 2024
- Terumo automates manufacturing to expand cell & gene therapies - European Pharmaceutical Manufacturer - November 3rd, 2024
- 12-Year-Old Leaves Washington DC Hospital As The First Patient To Receive Approved Gene Therapy For Sickle Cell Disease - AfroTech - November 3rd, 2024
- Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire - November 3rd, 2024
- New FDA designations granted to NCATS for rare disease therapies. - NCBI - October 22nd, 2024
- $1.8 Million Awarded to Study the Durability of Gene Therapy - University of Arkansas Newswire - October 22nd, 2024
- By the numbers: US leads charge of cell and gene therapies - BioWorld Online - October 22nd, 2024
- University of Arkansas Researcher Awarded $1.8M for Gene Therapy Study - Arkansas Business - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - StockTitan - October 22nd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 16, 2024 - CGTLive - October 22nd, 2024
- Japan mulls ways to boost cell, gene therapy approvals - BioWorld Online - October 22nd, 2024
- A New Type of Gene Therapy Shows Promise for Treating Retinitis Pigmentosa - Managed Healthcare Executive - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 2 - BioPharm International - October 22nd, 2024
- When a Miracle Cure Is Left on the Shelf - Bloomberg - October 22nd, 2024
- Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31 - Business Wire - October 22nd, 2024
- MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial - Fierce Biotech - October 22nd, 2024
- 5 Sickle Cell Therapies to Watch Following Pfizers Oxbryta Exit - BioSpace - October 22nd, 2024
- Fiocruz and GEMMABio announce partnership for the development of gene therapies - Fiocruz - October 22nd, 2024
- JPMA on Japans Biotech Industry: Cancer, Cardiovascular, and Aging Lead Diseases; Antibody, Cell, and Gene Therapies Top the Innovation List -... - October 22nd, 2024
- Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR - PharmiWeb.com - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 3 - Pharmaceutical Technology Magazine - October 22nd, 2024
- The role of quality assurance in accelerating drug development for emerging therapies - pharmaphorum - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - The Manila Times - October 22nd, 2024
- Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market is projected to grow at a CAGR of - PharmiWeb.com - October 22nd, 2024
- Gene therapy: advances, challenges and perspectives - PMC - October 6th, 2024
- Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges - BioSpace - October 6th, 2024
- Ferring opens doors to Finnish manufacturing hub as supply of its bladder cancer gene therapy continues to grow - FiercePharma - October 6th, 2024
- Meet Boston's National STEM Champion who's a junior in high school studying gene therapy - CBS Boston - October 6th, 2024
- Gene therapy research offers hope for kids with life-altering condition - WCVB Boston - October 6th, 2024
- Is gene therapy the next big step in vision loss treatment? - Medical News Today - October 6th, 2024
- Protein's Role in Insulin Signaling Could Have Implications for Gene Therapy - AJMC.com Managed Markets Network - October 6th, 2024
- Scientists overcome major challenge in gene therapy and drug delivery - News-Medical.Net - October 6th, 2024
- Innovative gene therapy for hemophilia - healthcare-in-europe.com - October 6th, 2024
- The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites - PR Newswire - October 6th, 2024
- Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now - Quartz - October 6th, 2024
- Cell therapy weekly: Promising Phase I results for Parkinsons disease cell therapy - RegMedNet - October 6th, 2024
- Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic regulation of C-MYC - Nature.com - October 6th, 2024
- Forge Biologics Announces the FUEL AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production -... - October 6th, 2024
- Ninth Circuit Decision Marks Critical Legal Victory for U.S. FDA in Mission to Protect Patients from Unregulated Cell Therapy Products - PR Newswire - October 6th, 2024
- Gene therapy: What is it and how does it work? | Live Science - September 21st, 2024
- How Does Gene Therapy Work? Types, Uses, Safety - Healthline - September 21st, 2024
- In race to make gene therapy for age-related blindness, 4D Molecular announces positive results - STAT - September 21st, 2024
- Penn gene therapy pioneer Jim Wilson explains why he's leaving - The Business Journals - September 21st, 2024
- Whats the Meaning of Cure in Gene Therapy? - Managed Healthcare Executive - September 21st, 2024